EpiCast Report 2016: Hepatitis C Virus - Epidemiology Forecast to 2025 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025" drug pipelines to their offering.

In the 9MM, epidemiologists forecast that the anti-HCV+ total prevalent cases will increase from 19,842,780 total prevalent cases in 2015 to 20,886,113 total prevalent cases in 2025, at an Annual Growth Rate (AGR) of 0.53%. China will have the highest number of anti-HCV+ total prevalent cases among the 9MM throughout the forecast period, while Germany will have the lowest number of anti-HCV+ total prevalent cases.

In the 9MM, epidemiologists forecast that the HCV RNA+ total prevalent cases will increase from 9,932,624 total prevalent cases in 2015, to 10,399,601 total prevalent cases in 2025, at an AGR of 0.47%. In the 9MM, epidemiologists forecast that the anti-HCV+ diagnosed prevalent cases will increase from 5,681,205 diagnosed prevalent cases in 2015, to 5,944,944 diagnosed prevalent cases in 2025, at an AGR of 0.46%. In the 9MM, epidemiologists forecast that the HCV RNA+ diagnosed prevalent cases will increase from 2,992,433 diagnosed prevalent cases in 2015, to 3,115,901 diagnosed prevalent cases in 2025, at an AGR of 0.41%.

This forecast is supported by historical data from government reports and national studies published in peer-reviewed journals. All data used for the analysis were country-specific. All studies that were used confirmed anti-HCV+ and HCV RNA+ total prevalent cases through laboratory diagnostic tests. Also, epidemiologists did not include studies that oversampled the high-risk population groups, such as IDUs, as we believe this would inflate the anti-HCV+ total prevalence.

Furthermore, additional segmentation of the anti-HCV+ diagnosed prevalent cases by age, sex, and liver cirrhosis status will provide the most refined and granular forecast results. The forecast methodology was also consistent across the 9MM, thereby allowing for a meaningful comparison of the forecast numbers in these markets.

Key Topics Covered:

1 Tables & Figures

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global Trends

2.3.1 Diagnosed Incidence and Total Prevalence

2.3.2 Genotype

2.4 Forecast Methodology

2.5 Epidemiological Forecast of HCV (2015-2025)

2.5.1 Total Prevalent Cases

2.5.2 Diagnosed Prevalent Cases

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 Limitations of the Analysis

2.6.3 Strengths of the Analysis

3 Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/3vwcg5/epicast_report

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Infectious Diseases Drugs, Infectious Disease Testing, Liver and Kidney Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Infectious Diseases Drugs, Infectious Disease Testing, Liver and Kidney Disorders Drugs